Resveratrol for Patients With Colon Cancer
Resveratrol is purported to possess cancer preventive activity, especially for colon cancer, though its mechanisms of action are not well defined. Resveratrol is found in the skin of grapes and has anti-oxidative and pro-apoptotic effects on cancer cell lines in vitro. The main dietary sources of resveratrol are grapes, grape products, and red wine, and small amounts may be found in mulberries. A prior report and compelling preliminary data from our laboratory suggest that resveratrol modulates Wnt signaling, a signaling pathway which is activated in over 85% of colon cancers. In this proposal, studies were performed to define the actions of resveratrol on the Wnt signaling pathway in a clinical trial in which patients with colon cancer received treatment with Resveratrol, and correlative laboratory studies examined its effects directly on colon cancer and normal colonic mucosa. These studies provided data on the mechanisms of resveratrol action and provided a foundation for future prevention trials, correlative studies and therapeutic clinical research with this agent.
Description
Patients will be treated with a two-week course of resveratrol. The initiation of the treatment will be approximately 14 days before standard of care surgical resection of tumor. Resveratrol will be ingested as 20 mg pills or in the form of freeze-dried grape extract which is prepared by the California Table Grape Commission used under GMP guidelines for human consumption.
The first two patients receiving resveratrol will be treated at a dose of 20 mg/day, the third and fourth patients at a dose of 80 mg/day, and the fifth and sixth patients with a dose of 160 mg/day. All patients receiving grape extract will receive 125 mg/day that will have to be mixed with one 8 oz glass of water. There will be no dose adjustments. If a patient has any side effects which are attributed to the resveratrol, it will be discontinued.
Status: Completed (Phase 1). Started on July 1st, 2005.
Enrollment: 11 subjects
Study Type: Interventional
Study Design:
- Allocation: Non-Randomized
- Endpoint Classification: Efficacy Study
- Intervention Model: Single Group Assignment
- Masking: Open Label
- Primary Purpose: Treatment
Conditions:
Interventions:
- Drug: Resveratrol
Eligibility
Inclusion Criteria:
Patients diagnosed with colon cancer by colonoscopic biopsy and tissue obtained under UCI04-05.
Patients with a plan for surgical resection at UCIMC within 2-4 weeks of enrollment.
Exclusion Criteria:
Surgical resection to be performed at a facility other than UCIMC.
Patients under 18 years of age.
- Gender
Both
- Mininum Age
18 Years
- Maximum Age
N/A
- Healthy Volunteers
No
Resources
Source: University of California, Irvine
Authority: United States: Institutional Review Board
Locations
-
Chao Family Comprehensive Cancer Center
Orange
California
92868
United States
Officials
Randall Holcombe, MD (Principal Investigator, University of California, Irvine)
Sponsors
University of California, Irvine (Lead Sponsor)
University of California, Los Angeles (Collaborator)
References
None.
Links
- Date Verified
- August 1st, 2011
- First Received
- August 15th, 2011
- Last Changed
- August 15th, 2011
Information obtained from ClinicalTrials.gov on August 15, 2011. Link to the current ClinicalTrials.gov record.
All data in the Healia Clinical Trials Information Database and content displayed by the Healia Clinical Trials Search Engine are licensed from the National Institutes of Health (National Library of Medicine), which collects and maintains the data.
The Healia Clinical Trials Search Engine searches the data set at clinicaltrials.gov, providing up-to-date information about current clinical trials. In the Healia Clinical Trials Database you can find information on new experimental drugs, medical devices, and other types of treatments for all types of diseases. Each clinical trial description includes information about the phase of the trial (phase I, phase II, or phase III), the trial’s methods, such as whether it is a randomized, placebo controlled, double blind study, and the status of the trial including whether or not the trial is currently enrolling new participants.